BML Capital Management, LLC
CIK: 0001616824Latest portfolio: $115.7M · Q4 2025
Holdings
16
Total Value
$115.7M
New Positions
5
Closed Positions
7
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ACRSACLARIS THERAPEUTICS INC | 14,250,000 | $42.9M | 37.08% | — | |
| 2 | AVIRATEA PHARMACEUTICALS INC | 7,490,000 | $26.7M | 23.11% | +16K | |
| 3 | ORMPORAMED PHARMACEUTICALS INC | 3,167,231 | $9.0M | 7.80% | — | |
| 4 | TILINSTIL BIO INC | 645,600 | $7.1M | 6.14% | — | |
| 5 | PMVPPMV PHARMACEUTICALS INC | 5,292,000 | $6.6M | 5.72% | — | |
| 6 | KMXCARMAX INC | 155,000 | $6.0M | 5.18% | NEW | |
| 7 | KZRKEZAR LIFE SCIENCES INC | 720,787 | $4.5M | 3.92% | — | |
| 8 | DYHTARGET CORP | 37,500 | $3.7M | 3.17% | +28K | |
| 9 | CVNACARVANA CO | 150 | $2.0M | 1.74% | NEW | Put |
| 10 | OMOUTSET MED INC | 543,180 | $2.0M | 1.74% | NEW | |
| 11 | PLRXPLIANT THERAPEUTICS INC | 1,546,137 | $1.9M | 1.63% | NEW | |
| 12 | IMAIMAGENEBIO INC | 177,026 | $1.2M | 1.06% | -5,483 | |
| 13 | CNTBCONNECT BIOPHARMA HLDGS LTD | 408,887 | $1.2M | 1.00% | -858,613 | |
| 14 | WMTWALMART INC | 335 | $492K | 0.43% | +70 | Put |
| 15 | TSLATESLA INC | 1,000 | $205K | 0.18% | NEW | Put |
| 16 | LSTALISATA THERAPEUTICS INC | 73,348 | $136K | 0.12% | -36,493 |
Quarterly Changes
Sector Breakdown
Healthcare0.0% ($4.289226739902672e+35T)
Consumer Cyclical0.0% ($59.9T)
Unknown0.0% ($3.7M)
Consumer Defensive0.0% ($492K)
Filing History
Fund Information
BML Capital Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $115.7M across 16 holdings. The largest position is ACLARIS THERAPEUTICS INC (ACRS), representing 37.1% of the portfolio. Compared to the previous quarter, the fund opened 5 new positions and closed 9 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.